Evaluation of efficacy and safety of Dabigaran in patients with catheter ablation for atrial fibrillation.

Evaluation of efficacy and safety of Dabigaran in patients with catheter ablation for atrial fibrillation. - Evaluation of efficacy and safety of Dabigaran during catheter ablation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011223

Enrollment

140

Registered

2013-07-19

Start date

2013-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with symptomatic paroxysmal or persistent atrial fibrillation and no valvular diseases.

Exclusion criteria

Exclusion criteria: Patients with chronic atrial fibrillation, valvular heart diseases, severe renal dysfunction, history of allergy of this drug, bleeding tendency, high risk of bleeding, subdural catheter, and antithrombotic drugs.

Design outcomes

Primary

Measure	Time frame
Cerebral bleeding and stroke, systematic embolism, bleeding complication	—

Secondary

Measure	Time frame
Abnormal finding in blood test	—

Countries

Japan

Contacts

Public ContactKiyoko Ogino

Osaka City University Hospital Department of ethics

ethics@med.osaka-cu.ac.jp06-6645-3439

Outcome results